Overview
Tirzepatide is a dual receptor agonist, engaging both GIP and GLP-1 receptor pathways — one of the most extensively studied compounds in incretin-pathway research. The 60mg vial is the largest Tirzepatide size Nova Biolabs stocks, giving researchers the lowest price per milligram across the range.
Nova Biolabs supplies Tirzepatide 60mg in lyophilised form from UK domestic stock, HPLC-verified at >98% purity.
Key Research Areas
GIP/GLP-1 Pathway Research
Simultaneous engagement of both incretin receptor pathways makes Tirzepatide a widely-used tool for studying combined-pathway metabolic signalling.
Extended & Multi-Arm Studies
The 60mg vial supports research programmes running multiple experimental arms or longer timeframes without needing to reorder mid-study.
Insulin Sensitivity Studies
Its dual-agonist profile is frequently used in research examining insulin sensitivity pathways alongside appetite-regulation signalling.
Comparative Incretin Research
As one of the most studied dual agonists, Tirzepatide is often used as a reference compound in comparative incretin-pathway research against triple agonists such as Retatrutide.
Product Specifications
| Format | Lyophilised powder |
| Quantity | 60mg per vial |
| Purity | >98% (HPLC verified) |
| Storage | Refrigerate at 2–8°C. Stable 24 months lyophilised. |
| Origin | UK domestic stock |
| Research use | In vitro / laboratory use only |
Frequently Asked Questions
Commonly Stacked With
Compounds researchers often study alongside this one, and why.
Both feature in Nova’s Performance Bundle — MOTS-c is studied for mitochondrial/metabolic signalling alongside GLP-1/GIP receptor research, a common combined-goal pairing.
Paired in the Metabolic Research Bundle — 5-Amino-1MQ’s NNMT-inhibition research is often studied alongside incretin receptor agonists for broader metabolic pathway coverage.
Researchers running extended GLP-1/GIP protocols often study tissue-repair peptides alongside them, given the caloric-deficit context of appetite-signalling research.